The 2012 fungal meningitis outbreak: what a sterility failure looks like
A 2012 sterility failure in compounded steroid injections sickened more than 700 people across 20 states and killed 64.
A 2012 sterility failure in compounded steroid injections sickened more than 700 people across 20 states and killed 64.

In 2012, a multistate outbreak of fungal meningitis traced back to a single compounding pharmacy. The CDC's investigation, with reporting from CIDRAP and the NABP, reconstructed what happened.
The product was preservative-free methylprednisolone acetate, made by the New England Compounding Center in Framingham, Massachusetts. It was injected mostly for back pain. The contaminant was the fungus Exserohilum rostratum, which the CDC confirmed in unopened vials — meaning the contamination was in the product before it left the facility, not introduced at the clinic.
The human cost was severe. The CDC put the death toll at 64 as of October 2013, with more than 700 people sickened across 20 states. In 2013, Congress increased federal oversight of compounding pharmacies in response.
The lesson is narrow and important. "Sterile" is a claim, and it is a claim that only a proper sterility test can support. A product can look clear, be packaged cleanly, and still harbor viable microorganisms — here, a mold growing inside an injection vial. Bioburden testing, which counts microbes, is not the same as sterility testing, which is a 14-day pass/fail incubation looking for any growth. The difference matters most for anything injected, where the bloodstream is the delivery route and a single viable organism can be catastrophic.
This is the reason a certificate of analysis for an injectable-form product carries a sterility line — not a count, but a pass/fail from USP <71> — alongside the identity, purity, and content results. A COA without sterility on an injectable is missing the one test that failure makes unforgettable.
CDC multistate outbreak investigation; reporting by CIDRAP and NABP.
Regulator2024An FDA advisory committee presentation explained how peptide impurities, including aggregates, can raise immunogenicity risk.
Explainer2024Arsenic, cadmium, lead and mercury — where they come from, how they are measured, and the limits that apply.
Explainer2024Deletion sequences, oxidation products, aggregates and synthesis byproducts — and why an impurity profile belongs on a COA.